Newsroom

Newsroom

NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014

Press Release
Read More

NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms

Press Release
Read More

MultiOmyx™: A novel chemistry and visualization tools to aid resolution of discrepant Hodgkin Lymphoma cases. A single slide multiplex assay for the evaluation of classical Hodgkin Lymphoma

Literature
Read More

NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013

Press Release
Read More

NeoGenomics Schedules its Q3 2013 Earnings Release for October 23, 2013

Press Release
Read More

NeoGenomics Revises Upward its Quarter 3 2013 Guidance

Press Release
Read More

Highly multiplexed single-cell analysis of formalinfixed, paraffin-embedded cancer tissue

Literature
Read More

MultiOmyx™: A novel multiplex methodology for the evaluation of Hodgkin Lymphoma

Literature
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients